International Renal Research Institute of Vicenza, Vicenza, Italy.
Department of Nephrology, Dialysis and Transplantation, St. Bortolo Hospital, aULSS8 Berica, Vicenza, Italy.
Blood Purif. 2022;51(2):138-146. doi: 10.1159/000516411. Epub 2021 May 25.
Medium cutoff (MCO) membranes represent an interesting innovation in the field of hemodialysis. Given the correlation between large (PM >25 kDa) middle molecules (LMM) and clinical outcomes, the possibility to broaden the spectrum of solutes removed in hemodialysis with MCO membranes introduces a new perspective for end-stage kidney disease patients. Due to low diffusion coefficients of LMM, the use of convection is required to maximize extracorporeal clearance. High convective rates are achieved with high-flux membranes in hemodiafiltration, a technique not available in the US. In case of the MCO membrane, remarkable clearances of LMM are achieved combining the permeability of the membrane with a significant amount of internal convection. The mechanism of filtration-backfiltration inside the dialyzer enables effective removal of LMM in a technique called expanded hemodialysis (HDx). Given such theoretical explanation, it is important to demonstrate the blood and ultrafiltration rheology inside the MCO dialyzer.
This study for the first time describes flow dynamic parameters and internal cross-filtration, thanks to specific radiology and nuclear imaging techniques.
Flow dynamic analysis of the blood and dialysate compartment confirms excellent distribution of velocities and an excellent matching of blood and dialysate. Average blood flow velocity allows for wall shear rates adequate to avoid protein stagnation at the blood membrane interface and increase in blood viscosity. Cross-filtration analysis demonstrates a remarkable filtration/backfiltration flux reaching values >30 mL/min at a blood flow of 300 mL/min and zero net filtration.
The MCO dialyzer Theranova 400 appears to have a design optimized to perform expanded hemodialysis (HDx).
中分子截止(MCO)膜是血液透析领域的一项创新。鉴于大(PM>25 kDa)中分子(LMM)与临床结果之间存在相关性,使用 MCO 膜拓宽血液透析中可去除溶质的范围为终末期肾病患者带来了新的视角。由于 LMM 的扩散系数较低,需要使用对流来最大限度地提高体外清除率。在血液透析滤过中使用高通量膜可实现高对流率,而美国没有这种技术。对于 MCO 膜,通过膜的渗透性和大量内部对流相结合,可实现 LMM 的显著清除率。在称为扩展血液透析(HDx)的技术中,透析器内的过滤-反过滤机制可有效去除 LMM。鉴于这种理论解释,重要的是要证明 MCO 透析器内的血液和超滤流体力。
这项研究首次使用特定的放射学和核成像技术描述了血流动力学参数和内部交叉过滤。
血液和透析液腔的流动力学分析证实了速度的出色分布和血液与透析液的出色匹配。平均血流速度允许壁剪切率足以避免蛋白质在血液膜界面处停滞和血液粘度增加。交叉过滤分析表明,过滤/反过滤通量非常显著,在血流为 300 毫升/分钟时达到>30 毫升/分钟的流量,且净过滤为零。
Theranova 400 MCO 透析器的设计似乎经过优化,可进行扩展血液透析(HDx)。